Literature DB >> 11812578

Bipolar disorder.

Bruno Müller-Oerlinghausen1, Anne Berghöfer, Michael Bauer.   

Abstract

Bipolar, or manic-depressive, disorder is a frequent, severe, mostly recurrent mood disorder associated with great morbidity. The lifetime prevalence of bipolar disorder is 1.3 to 1.6%. The mortality rate of the disease is two to three times higher than that of the general population. About 10-20% of individuals with bipolar disorder take their own life, and nearly one third of patients admit to at least one suicide attempt. The clinical manifestations of the disease are exceptionally diverse. They range from mild hypomania or mild depression to severe forms of mania or depression accompanied by profound psychosis. Bipolar disorder is equally prevalent across sexes, with the exception of rapid cycling, a severe and difficult to treat variant of the disorder, which arises mostly in women. Because of the high risk of recurrence and suicide, long-term prophylactic pharmacological treatment is indicated. Lithium salts are the first choice long-term preventive treatment for bipolar disorder. They also possess well documented antisuicidal effects. Second choice prophylactic treatments are carbamazepine and valproate, although evidence of their effectiveness is weaker.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11812578     DOI: 10.1016/S0140-6736(02)07450-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  68 in total

1.  The management of acute mania.

Authors:  Paul E Keck
Journal:  BMJ       Date:  2003-11-01

2.  Association of 14-3-3 epsilon gene haplotype with completed suicide in Japanese.

Authors:  Masaya Yanagi; Osamu Shirakawa; Noboru Kitamura; Kenji Okamura; Kaoru Sakurai; Naoki Nishiguchi; Takeshi Hashimoto; Hideyuki Nushida; Yasuhiro Ueno; Daiji Kanbe; Meiko Kawamura; Kazuaki Araki; Hiroyuki Nawa; Kiyoshi Maeda
Journal:  J Hum Genet       Date:  2005-04-19       Impact factor: 3.172

3.  Genomewide scan for affective disorder susceptibility Loci in families of a northern Swedish isolated population.

Authors:  Tine Venken; Stephan Claes; Samuel Sluijs; Andrew D Paterson; Cornelia van Duijn; Rolf Adolfsson; Jurgen Del-Favero; Christine Van Broeckhoven
Journal:  Am J Hum Genet       Date:  2004-12-21       Impact factor: 11.025

4.  Long-term lithium treatment and thyroid antibodies: a controlled study.

Authors:  Christopher Baethge; Holger Blumentritt; Anne Berghöfer; Tom Bschor; Tasha Glenn; Mazda Adli; Peter Schlattmann; Michael Bauer; Reinhard Finke
Journal:  J Psychiatry Neurosci       Date:  2005-11       Impact factor: 6.186

Review 5.  Managing the acute psychotic episode.

Authors:  Peter Byrne
Journal:  BMJ       Date:  2007-03-31

6.  Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder.

Authors:  Matthew A Seager; Vanessa N Barth; Lee A Phebus; Kurt Rasmussen
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

7.  Does the use of an automated tool for self-reporting mood by patients with bipolar disorder bias the collected data?

Authors:  Michael Bauer; Natalie Rasgon; Paul Grof; Laszlo Gyulai; Tasha Glenn; Peter C Whybrow
Journal:  MedGenMed       Date:  2005-08-25

8.  [Bipolar depression. Epidemiology, etiopathogenesis, and course].

Authors:  S Haack; A Pfennig; M Bauer
Journal:  Nervenarzt       Date:  2010-05       Impact factor: 1.214

9.  Analytical performance evaluation of a new turbidimetric immunoassay for valproic acid on the ADVIA 1650 analyzer: effect of gross hemolysis and high bilirubin.

Authors:  Pradip Datta; Amitava Dasgupta
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

10.  Positive association between the PDLIM5 gene and bipolar disorder in the Chinese Han population.

Authors:  Teng Zhao; Yun Liu; Peng Wang; Sheng Li; Daizhan Zhou; Di Zhang; Zhuo Chen; Ting Wang; He Xu; Guoyin Feng; Lin He; Lan Yu
Journal:  J Psychiatry Neurosci       Date:  2009-05       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.